Breakthrough in Cystic Fibrosis Treatment Revealed Through Research

Strategic Insights -

Researchers at Duke University have made a significant breakthrough in the treatment of cystic fibrosis (CF) by investigating the effects of Elexacaftor/Tezacaftor/Ivacaftor (ETI) on the sinonasal airspace of individuals with CF. The study found that ETI therapy led to significant increases in sinonasal airspace surface area and volume, which correlated with improvements in Lund-Mackay scores but not SNOT-22 scores.

Key Takeaways:

  • The study used volumetric quantification technique to evaluate changes in CF sinonasal airway patency pre-ETI and post-ETI in 19 individuals with CF.
  • ETI therapy resulted in significant increases in sinonasal airspace surface area (from 251.97 cm^2 to 295.77 cm^2) and volume (from 44.86 cm^3 to 61.03 cm^3) post-treatment.
  • The increases in both parameters showed strong significant correlations with Lund-Mackay scores but not SNOT-22 scores.
  • The research was funded by the Cystic Fibrosis Foundation and was conducted at Duke University.
  • The study used radiographical images to reconstruct anatomically accurate person-specific three-dimensional sinonasal airspaces.

Statistics:

  • Surface area increase: 43.8% (from 251.97 cm^2 to 295.77 cm^2)
  • Volume increase: 35.5% (from 44.86 cm^3 to 61.03 cm^3)
  • Median surface area pre-ETI: 251.97 cm^2 (IQR: 43.71)
  • Median volume pre-ETI: 44.86 cm^3 (IQR: 20.72)
  • Median surface area post-ETI: 295.77 cm^2 (IQR: 31.34)
  • Median volume post-ETI: 61.03 cm^3 (IQR: 14.21)

Sources:

  • "Effects of Elexacaftor/tezacaftor/ivacaftor On the Sinonasal Airspace In Cystic Fibrosis" published in The Laryngoscope, 2025.
  • NewsRx. New Findings from Duke University in the Area of Cystic Fibrosis Described (Effects of Elexacaftor/tezacaftor/ivacaftor On the Sinonasal Airspace In Cystic Fibrosis). Respiratory Therapeutics Week. October 20, 2025; p 2735.
  • Wiley. The Laryngoscope. 111 River St, Hoboken 07030-5774, NJ, USA.